Jussi Sane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jussi Sane has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Wilfrid van Pelt
National Institute for Public Health and the Environment Bilthoven The Netherlands
2 shared publicationsBarbara Schimmer
1 shared publicationCorien Swaan
1 shared publicationHester de Melker
1 shared publicationJacinta Bakker
1 shared publicationJohan Reimerink
1 shared publication
Latest Publications
- 1 May 2015
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 22 (3) , 208-211
Risk of Hepatitis A Decreased Among Dutch Travelers to Endemic Regions in 2003 to 2011
We divided the number of travel-related hepatitis A cases notified in Dutch surveillance (2003-2011) by travel data obtained from an annual holiday survey to estimate the risk of hepatitis A among Dutch travelers. Of the 2,094 cases notified, 931 (44%) were imported. Morocco (n = 272, 29%), Turkey (n = 98, 11%), and Egypt (n = 87, 9%) accounted for the largest proportion of cases. Attack rates in returnees from high or intermediate endemic regions declined from 7.5 per 100,000 travelers (95% CI 6.7-8.4) in 2003-2005 to 3.5 (95% CI 3.0-4.0) in 2009-2011 (p < 0.01). Despite the decrease in risk, vaccination remains important, and routine risk monitoring should also be considered.
- 1 May 2015
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 22 (3) , 208-211
Risk of Hepatitis A Decreased Among Dutch Travelers to Endemic Regions in 2003 to 2011
We divided the number of travel-related hepatitis A cases notified in Dutch surveillance (2003-2011) by travel data obtained from an annual holiday survey to estimate the risk of hepatitis A among Dutch travelers. Of the 2,094 cases notified, 931 (44%) were imported. Morocco (n = 272, 29%), Turkey (n = 98, 11%), and Egypt (n = 87, 9%) accounted for the largest proportion of cases. Attack rates in returnees from high or intermediate endemic regions declined from 7.5 per 100,000 travelers (95% CI 6.7-8.4) in 2003-2005 to 3.5 (95% CI 3.0-4.0) in 2009-2011 (p < 0.01). Despite the decrease in risk, vaccination remains important, and routine risk monitoring should also be considered.
- Open Access
- 1 December 2014
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 20 (12) , 2107-2110
Human Hantavirus Infections in the Netherlands
We report the recent epidemiology and estimated seroprevalence of human hantavirus infections in the Netherlands. Sixty-two cases were reported during December 2008–December 2013. The estimated seroprevalence in the screened municipalities in 2006–2007 was 1.7% (95% CI 1.3%–2.3%). Findings suggest that hantavirus infections are underdiagnosed in the Netherlands.
- 1 December 2014
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 20 (12) , 2107-2110
Open AccessHuman Hantavirus Infections in the Netherlands
We report the recent epidemiology and estimated seroprevalence of human hantavirus infections in the Netherlands. Sixty-two cases were reported during December 2008–December 2013. The estimated seroprevalence in the screened municipalities in 2006–2007 was 1.7% (95% CI 1.3%–2.3%). Findings suggest that hantavirus infections are underdiagnosed in the Netherlands.
- Open Access
- 1 April 2014
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 20 (4) , 643-648
Epidemic of Mumps among Vaccinated Persons, the Netherlands, 2009–2012
To analyze the epidemiology of a nationwide mumps epidemic in the Netherlands, we reviewed 1,557 notified mumps cases in persons who had disease onset during September 1, 2009–August 31, 2012. Seasonality peaked in spring and autumn. Most case-patients were males (59%), 18–25 years of age (67.9%), and vaccinated twice with measles-mumps-rubella vaccine (67.7%). Nearly half (46.6%) of cases occurred in university students or in persons with student contacts. Receipt of 2 doses of vaccine reduced the risk for orchitis, the most frequently reported complication (vaccine effectiveness [VE] 74%, 95% CI 57%–85%); complications overall (VE 76%, 95% CI 61%–86%); and hospitalization (VE 82%, 95% CI 53%–93%). Over time, the age distribution of case-patients changed, and proportionally more cases were reported from nonuniversity cities (p<0.001). Changes in age and geographic distribution over time may reflect increased immunity among students resulting from intense exposure to circulating mumps virus.
- 1 April 2014
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 20 (4) , 643-648
Open AccessEpidemic of Mumps among Vaccinated Persons, the Netherlands, 2009–2012
To analyze the epidemiology of a nationwide mumps epidemic in the Netherlands, we reviewed 1,557 notified mumps cases in persons who had disease onset during September 1, 2009–August 31, 2012. Seasonality peaked in spring and autumn. Most case-patients were males (59%), 18–25 years of age (67.9%), and vaccinated twice with measles-mumps-rubella vaccine (67.7%). Nearly half (46.6%) of cases occurred in university students or in persons with student contacts. Receipt of 2 doses of vaccine reduced the risk for orchitis, the most frequently reported complication (vaccine effectiveness [VE] 74%, 95% CI 57%–85%); complications overall (VE 76%, 95% CI 61%–86%); and hospitalization (VE 82%, 95% CI 53%–93%). Over time, the age distribution of case-patients changed, and proportionally more cases were reported from nonuniversity cities (p<0.001). Changes in age and geographic distribution over time may reflect increased immunity among students resulting from intense exposure to circulating mumps virus.